Palonosetron (Aloxi): a second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting.

@article{Leon2006PalonosetronA,
  title={Palonosetron (Aloxi): a second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting.},
  author={Andrew De Leon},
  journal={Proceedings},
  year={2006},
  volume={19 4},
  pages={
          413-6
        }
}
In July 2003, the Food and Drug Administration approved palonosetron hydrochloride injection for the treatment of chemotherapy-induced nausea and vomiting (CINV). The newest agent in the class of 5-HT₃ receptor antagonists (5-HT₃RAs), palonosetron differs from other agents in its class by its higher receptor-binding affinity and longer half-life. These pharmacological properties have resulted in improved antiemetic activity in clinical trials, particularly in the treatment of delayed CINV… CONTINUE READING

Similar Papers

Tables and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-9 OF 9 REFERENCES

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006

Palonosetron is effective in preventing acute and delayed chemotherapy - induced nausea and vomiting in patients receiving highly emetogenic chemotherapy [ abstract A - 17 ]

MS Aapro, L Bertoli, F Lordic
  • Support Care Cancer
  • 2003

Prevention of non - cisplatin induced emesis : role of the antagonists of 5 - HT receptors

B Massidda, S Laconi, MR Foddi
  • Ann Oncol
  • 1994